Novartis, CH0012005267

Morgan Stanley cuts target for Novartis stock to USD 156.00

Published on 10/13/2026 at 13:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis schedules third-quarter results for October 27, 2026. Novartis stock costs EUR 130.37 on October 13, 2026 at 1:07 p.m. CEST.

Morgan Stanley cut its Novartis target from USD 170.00 to USD 156.00 on October 6, 2026.
Novartis will publish third-quarter 2026 results on October 27, 2026.
Novartis stock costs EUR 130.37 at Lang & Schwarz on October 13, 2026 at 1:07 p.m. CEST.
The price-to-earnings ratio was 22.26 and market capitalization was USD 273.4 billion on October 12, 2026.

Pharmatechniker an Tablettenpresse, dokumentarische SW-Fotografie mit Industrieatmosphäre — Novartis AG CH0012005267 – Pharmatechniker bedient eine industrielle Tablettenpresse in dokumentarischer Schwarzweißfotografie, Illustration mit AI erstellt.

Morgan Stanley analyst Thibault Boutherin cut the price target for Novartis stock from USD 170.00 to USD 156.00 on October 6, 2026, while keeping an Overweight rating, according to Markets Insider. Novartis stock was trading at EUR 130.37 at Lang & Schwarz on October 13, 2026 at 1:07 p.m. CEST.

Results arrive on October 27

Novartis has scheduled its third-quarter 2026 results for October 27, 2026, according to the company's investor-relations page. The webcast is set for 1:00 p.m. CET, giving investors a defined date for the next operating update.

The timing matters because the October 6 target reduction came ahead of that report. Morgan Stanley lowered its target by USD 14.00, a 8.24 percent cut from USD 170.00, but retained its positive Overweight view.

Stock remains below its yearly high

The euro quote of EUR 130.37 stood below the 52-week high of EUR 144.08 reported for October 12, 2026. The gap was 9.51 percent, calculated from the quoted price and high, while the 52-week low was EUR 105.88.

The same dated market snapshot listed a one-week performance of plus 2.92 percent and a one-month performance of plus 7.05 percent. Those figures place the current quote above the recent one-month level while leaving it below the yearly peak.

Valuation before the next update

Novartis had a market capitalization of USD 273.4 billion and a price-to-earnings ratio of 22.26 as of October 12, 2026. The finance snapshot also showed a trailing dividend yield of 0.03 percent and average volume of 1,963,414 shares.

The valuation backdrop is mixed in a specific way: the target cut lowers Morgan Stanley's numerical upside framework, while the October 27 results date creates the next measured test for revenue, earnings and management commentary.

Price and trading reference

Novartis stock was trading at EUR 130.37 at Lang & Schwarz on October 13, 2026 at 1:07 p.m. CEST. The bid was EUR 130.34 and the ask was EUR 130.40, keeping the quoted spread at EUR 0.06.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.